deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
24997Bk(n,γ)25097Bk → 25098Cf + β− Bombardment of 250Cf with neutrons produces 251Cf and 252Cf. Prolonged irradiation of americium, curium, and plutonium with neutrons produces milligram amounts of 252Cf and microgram amounts of 249Cf. As of 2006, curium isotopes 244 to 248 are irradiated by neutrons in special reactors to produce mainly californium-252 with lesser amounts of isotopes 249 to 255. Microgram quantities of 252Cf are available for commercial use through the U.S. Nuclear Regulatory Commission. Only two sites produce 252Cf: Oak Ridge National Laboratory in the U.S., and the Research Institute of Atomic Reactors in Dimitrovgrad, Russia. As of 2003, the two sites produce 0.25 grams and 0.025 grams of 252Cf per year, respectively. Three californium isotopes with significant half-lives are produced, requiring a total of 15 neutron captures by uranium-238 without nuclear fission or alpha decay occurring during the process. 253Cf is at the end of a production chain that starts with uranium-238, and includes several isotopes of plutonium, americium, curium, and berkelium, and the californium isotopes 249 to 253 (see diagram).
In the late 1990s, some investigators thought that the fact that symptoms emerged when antidepressants were discontinued might mean that antidepressants were causing addiction, and some used the term "withdrawal syndrome" to describe the symptoms. While people taking antidepressants do not commonly exhibit drug-seeking behavior, stopping antidepressants leads to similar symptoms as found in drug withdrawal from benzodiazepines, and other psychotropic drugs. As such, some researchers advocate the term withdrawal over discontinuation, to communicate the similar physiological dependence and negative outcomes. Due to pressure from pharmaceutical companies who make antidepressants, the term "withdrawal syndrome" is no longer used by drug makers, and thus, most doctors, due to concerns that they may be compared to other drugs more commonly associated with withdrawal.
The puruṣamr̥ga plays a significant role in daily as well as yearly ritual of South Indian Hindu temples. In the Shodhasha-Upakaara (or sixteen honors) ritual, performed between one and six times at significant sacred moments through the day, it decorates one of the lamps of the Deepaaradhana or lamp ceremony. And in several temples the puruṣamr̥ga is also one of the vahana or vehicles of the deity during the processions of the Brahmotsava or festival. In Kanyakumari district, in the southernmost tip of the Indian subcontinent, during the night of Maha Shivaratri, devotees run 75 kilometres while visiting and worshiping at twelve Shiva temples. This Shiva Ottam or Running for Shiva is performed in commemoration of the story of the race between the Purushamirugam and Bhima, one of the Pandavas of the Hindu Epic Mahabharata. The Indian conception of a sphinx that comes closest to the classic Greco-Roman idea is the Sharabha and Gandabherunda, two mythical creatures, part lion, part human, part mammal and part bird, and the form of Sharabha that god Shiva took on and fought with the god Vishnu as Narasimha and Shiva as Sharabha was killed by Vishnu as Gandabherunda in the form of Narashima when Narashima killed Hiranyakashipu. In Sri Lanka and India, the sphinx is known as narasimha or human-lion. As a sphinx, it has the body of a lion and the head of a human being, and is not to be confused with Narasimha, the fourth incarnation of the deity Vishnu; this avatara or incarnation of Vishnu has a human body and the head of a lion and Vishnu as Narashima killed Hiranyakashipu.
== Diagnosis == No specific test exists to diagnose polymyalgia rheumatica; many other diseases can cause inflammation and pain in muscles, but a few tests can help narrow down the cause of the pain. Limitation in shoulder motion or swelling of the joints in the wrists or hands, are noted by the doctor. One blood test usually performed is the erythrocyte sedimentation rate (ESR) which measures how fast the patient's red blood cells settle in a test tube. The faster the red blood cells settle, the higher the ESR value (measured in mm/hour), which suggests that inflammation may be present. Many conditions can cause an elevated ESR, so this test alone is not proof that a person has polymyalgia rheumatica. Another test that checks the level of C-reactive protein (CRP) in the blood may also be conducted. CRP is produced by the liver in response to an injury or infection, and people with polymyalgia rheumatica usually have high levels. However, like the ESR, this test is also not very specific. Polymyalgia rheumatica is sometimes associated with temporal arteritis, a condition requiring more aggressive therapy. To test for this additional disorder, a biopsy sample may be taken from the temporal artery.
=== Direct calorimetry of combustion === The first determinations of the energy content of food were made by burning a dried sample in a bomb calorimeter and measuring the temperature change in the water surrounding the apparatus, a method known as direct calorimetry.
Sources: en.wikipedia.org
== Industrial use == Butane-1,4-diol is used industrially as a solvent and in the manufacture of some types of plastics, elastic fibers and polyurethanes. In organic chemistry, 1,4-butanediol is used for the synthesis of γ-butyrolactone (GBL). In the presence of phosphoric acid and high temperature, it dehydrates to the important solvent tetrahydrofuran. At about 200 °C in the presence of soluble ruthenium catalysts, the diol undergoes dehydrogenation to form butyrolactone. It is used to synthesize 1,4-butanediol diglycidyl ether which is then used as a reactive diluent for epoxy resins. 1,4-Butanediol is used in the production of polybutylene terephthalate (PBT) plastic. World production of butane-1,4-diol was claimed to be about one million metric tons per year and market price is about US$2,000 (€1,600) per ton in 2005. In 2013, worldwide production was claimed to be billions of pounds (consistent with approximately one million metric tons). Almost half of it is dehydrated to tetrahydrofuran to make fibers such as Spandex. The largest producer is BASF.
== Prognosis == The median survival in idiopathic pulmonary fibrosis is 3–3.5 years. However, prognosis varies widely depending on the specific type and cause of ILD; some inflammatory forms may stabilize or improve with treatment. ILD is associated with a 3-fold increased risk of lung cancer. Life expectancy after lung transplant is 5.2 years in those with idiopathic interstitial pneumonias (including idiopathic pulmonary fibrosis) and 6.7 years in those with other types of ILD.
=== Military use === As of 2012, the United States Air Force used zolpidem as one of the hypnotics approved as a "no-go pill" with a six-hour restriction on subsequent flight operation to help aviators and special duty personnel sleep in support of mission readiness. (The other hypnotics used are temazepam and zaleplon.) "Ground tests" are required before an authorization is issued to use the medication in an operational situation.
Maintaining potential control in in situ measurements preserves the electrochemical environment at the electrode–electrolyte interface, thereby keeping the double layer and ongoing electron-transfer reactions intact at a given electrode potential.
Sources: en.wikipedia.org
== Selected articles == Meyer, D. E., & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nature Biotechnology, 17(11), 1112–1115. Nath, N., & Chilkoti, A. (2002). A colorimetric gold nanoparticle sensor to interrogate biomolecular interactions in real time on a surface. Analytical chemistry, 74(3), 504–509. Ma, H., Hyun, J. Chilkoti, A. (2004). "Nonfouling" oligoethylene glycol functionalized polymer brushes synthesized by surface-initiated atom transfer radical polymerization. Advanced Materials, 16, 338–341. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 98(5), 335–344. Ciracì, C., Hill, R. T., Mock, J. J., Urzhumov, Y., Fernández-Domínguez, A. I., Maier, S. A., ... & Smith, D. R. (2012). Probing the ultimate limits of plasmonic enhancement. Science, 337(6098), 1072–1074.
Several scholars, lawmakers, intelligence agencies, and the members of the public expressed concerns about political violence surrounding the 2024 election. The fears came amidst increasing threats and acts of physical violence targeting public officials and election workers at all levels of government. Trump was identified as a key figure in increasing political violence in the United States both for and against him. Political violence was at its highest since the 1970s, and the most recent violence came from right-wing assailants. Trump increasingly embraced far-right extremism, conspiracy theories such as Q-Anon, and far-right militia movements to a greater extent than any modern American president. Trump also espoused dehumanizing, combative, and violent rhetoric, and promised retribution against his political enemies. Trump played down but refused to rule out violence following the 2024 election, stating "it depends". Trump also suggested using the military against "the enemy from within" on Election Day that he described as "radical left lunatics", Democratic politicians, and those opposed to his candidacy.
The March of the Chinese People's Liberation Army was adopted as the military anthem by the Central Military Commission on 25 July 1988. The lyrics of the anthem were written by composer Gong Mu (real name: Zhang Yongnian; Chinese: 张永年) and the music was composed by Korea-born Chinese composer Zheng Lücheng.
Peroxidases or peroxide reductases (EC number 1.11.1.x) are a large group of enzymes which play a role in various biological processes. They are named after the fact that they commonly break up peroxides, and should not be confused with other enzymes that produce peroxide, which are often oxidases.
Drug metabolism is the metabolic breakdown of drugs by humans and animals, usually through specialized enzymatic systems. Drug metabolism represents a more specialized subset of xenobiotic metabolism (from the Greek xenos "stranger" and biotic "related to living beings") which also covers other foreign organic compounds such as pollutants or poisons in wider group of organisms that includes microorganisms, fungi, plants and animals. These reactions often act to detoxify drugs (although in some cases the intermediates in drug metabolism may cause toxic effects). The study of drug metabolism is one of the tenets of pharmacokinetics (PK) as metabolism (M), the fourth stage of LADME (a drug's transit through the body), involves the enzymatic biotransformation and non-enzymatic biotransformation of a drug, thereby leading to the fifth stage, excretion (E). The metabolism of pharmaceutical drugs is an important aspect of pharmacology and medicine. For example, the rate of metabolism determines the duration and intensity of a drug's pharmacologic action. Drug metabolism also affects multidrug resistance in infectious diseases and in chemotherapy for cancer, and the actions of some drugs as substrates or inhibitors of enzymes involved in xenobiotic metabolism are a common reason for hazardous drug interactions.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.